Source-grounded facts extracted from TuHURA Biosciences, Inc./NV's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TuHURA Biosciences, Inc./NV incurred revolving credit of $1,700,000 with Parkview Holdings One LLC maturing April 21, 2031.
“On May 26, 2026, the Company received its first draw under the revolving credit facility for an amount of $1,700,000 and expects to use the funds for general corporate purposes.”
TuHURA Biosciences, Inc./NV reported financial results for three months ended March 31, 2026.
“Summary of Financial Results for the First Quarter 2026 Cash and cash equivalents of $6.3 million at March 31, 2026. TuHURA's total common shares outstanding were approximately 63.6 million. Research and development expenses were $5.2 million and $4.6 million for the 3 months ended March 31, 2026, and 2025, respectively. General and administrative (G&A) expenses were $2.3 million and $2.0 million for the 3 months ended March 31, 2026, and 2025, respectively. Net cash outflows from operating activities were ($4.4) million and ($4.7) million for the 3 months ended March 31, 2026, and 2025, respectively. Net cash flows from financing activities were $ 7.2 million and $ (0.5) million for the 3 months ended March 31, 2026, and 2025, respectively.”
TuHURA Biosciences, Inc./NV issued common stock to Parkview Holdings One LLC for conversion price per share equal to $2.662.
“convert all outstanding principal plus accrued and unpaid interest into shares of Company common stock (“Conversion Shares”) at a conversion price per share equal to $2.662”
TuHURA Biosciences, Inc./NV issued 1,878,287 shares of common stock to Parkview Holdings One LLC for commitment fee equal to ten percent (10%) of the total commitment.
“pay a one-time loan commitment fee equal to ten percent (10%) of the total commitment under the Loan Agreement (resulting in a commitment fee of $5.0 million), which the Company has elected to pay by the issuance of an aggregate of 1,878,287 shares of Company common stock (the “Loan Fee Shares”) to Parkview”
TuHURA Biosciences, Inc./NV incurred revolving credit of $50 million revolving credit facility with Parkview Holdings One LLC at 12% per annum (plus additional 6% during an event of default) maturing April 21, 2031.
“On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement.”
TuHURA Biosciences, Inc./NV entered into Loan Agreement with Parkview Holdings One LLC valued at $50 million (effective 2026-04-21).
“On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement.”
TuHURA Biosciences, Inc./NV reported financial results for for the Company's fourth quarter and full year ended December 31, 2025.
“TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update”
TuHURA Biosciences, Inc./NV reported financial results for for the year ended December 31, 2025.
“On April 1, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the year ended December 31, 2025, and providing a corporate update.”
TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 29, 2026, TuHURA Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. Pursuant to Nasdaq Listing R”
TuHURA Biosciences, Inc./NV entered into Engagement Letter with H.C. Wainwright & Co., LLC.
“Pursuant to an Engagement Letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“HCW”), the Company agreed to pay HCW, as exclusive lead placement agent, and Rodman & Renshaw LLC, as co-placement agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate gross proceeds raised in the First Closing, (ii) a cash fee equal to 2.0% of the aggregate gross proceeds raised in the Second Closing and Third Closing, (iii) certain expenses including reasonable fees and expenses of counsel in an amount not to exceed $100,000, and (iv) $25,000 for non-accountable expenses.”
TuHURA Biosciences, Inc./NV entered into Side Letter with K&V Investment One LLC (effective 2025-12-09).
“On the same date, the Company and K&V Investment One LLC (“K&V”), a Purchaser in the Offering, entered into a side letter to the Purchase Agreement (the “Side Letter”)”
TuHURA Biosciences, Inc./NV entered into Purchase Agreement with certain investors (collectively, the "Purchasers") (effective 2025-12-09).
“On December 9, 2025, TuHURA Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (collectively, the “Purchasers”).”
TuHURA Biosciences, Inc./NV amended Amendment with Matthew Nachtrab Revocable Trust dated 12/18/2014 (effective 2025-12-02).
“Amendment to Secured Promissory Note and Loan Agreement As disclosed in a Current Report on Form 8-K filed by TuHURA Biosciences, Inc.”
TuHURA Biosciences, Inc./NV amended loan with Matthew Nachtrab Revocable Trust dated 12/18/2014.
“(the “Company”) on October 31, 2025, the Company previously entered into a Secured Promissory Note and Loan Agreement, dated October 27, 2025 (the “Loan Agreement”), with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the “Lender”). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3.0 million (the “Loans”) during a 30-day availability period beginning on the date of the Loan Agreement (the “Availability Period”).”
TuHURA Biosciences, Inc./NV incurred loan of $1.5 million with Matthew Nachtrab Revocable Trust dated 12/18/2014.
“the Company borrowed an additional $1.5 million from the Lender under the Loan Agreement (the “Second Loan”), which resulted in aggregate Loans of $3.0 million made to the Company under the Loan Agreement.”
TuHURA Biosciences, Inc./NV incurred loan of up to $3,000,000 with Matthew Nachtrab Revocable Trust dated 12/18/2014 at 3% per month maturing the earlier of December 31, 2025 or on the date that is 30 days following the successful closing of an equity financing in which the Company receives gross cash.
“Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3,000,000 (the “Loans”) during a 30-day availability period beginning on the date of the Loan Agreement.”
TuHURA Biosciences, Inc./NV completed an acquisition involving Kineta, Inc. for 0.185298 shares of TuHURA common stock per share, for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock (closed 2025-06-30).
“share of Kineta common stock, par value $0.001 per share (each, a “Share”), issued and outstanding immediately prior to the First Merger, was converted into the right to receive 0.185298 shares of TuHURA common stock, par value $0.001 per share (“TuHURA Common Stock”), for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock. Also pursuant to the”
TuHURA Biosciences, Inc./NV: Increased authorized shares of common stock from 75 million to 200 million (effective 2025-06-23).
“the stockholders of the Company approved an amendment to the Company's Articles of Incorporation increasing the number of authorized shares of common stock from 75 million to 200 million shares”
Dennis Yamashita was terminated as Chief Scientific Officer at TuHURA Biosciences, Inc./NV.
“the Separation Agreement confirms that Mr. Yamashita’s employment with TuHURA terminated effective December 16, 2024”
Craig Tendler was appointed as Director at TuHURA Biosciences, Inc./NV.
“On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”
TuHURA Biosciences, Inc./NV engaged Cherry Bekaert LLP as its auditor.
“On December 27, 2024, following the completion of the Merger, the Audit Committee of the Company’s board of directors unanimously approved the appointment of Cherry Bekaert as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2024.”
TuHURA Biosciences, Inc./NV dismissed Marcum LLP as its auditor.
“On December 31, 2024, as a result of completion of the Merger, Marcum was informed that it was dismissed as the Company’s independent registered public accounting firm.”
TuHURA Biosciences, Inc./NV underwent a change of control involving TuHURA Biosciences, Inc., a Delaware corporation (closed 2024-10-18).
“the completion of the Merger, pursuant to which Kayak Mergeco, Inc. merged with and into TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA")”
TuHURA Biosciences, Inc./NV: Kintara ceased to be a shell company as a result of the Merger.
“As a result of the Merger, Kintara ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the closing of the Merger.”
TuHURA Biosciences, Inc./NV: Company changed its fiscal year end from June 30 to December 31.
“In connection with the closing of the Merger, the Company changed its fiscal year end from June 30 to December 31, the fiscal year end of TuHURA prior to the Merger.”
TuHURA Biosciences, Inc./NV underwent a change of control (closed 2024-10-18).
“On October 18, 2024, the Nevada corporation formerly known as "Kintara Therapeutics, Inc." completed its previously announced merger transaction in accordance with the terms of the Agreement and Plan of Merger, dated as of April 2, 2024”
TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2024 results: net income net loss of approximately $2.0 million, EPS $0.05 per share.
“As of March 31, 2024, Kintara had cash and cash equivalents of approximately $6.35 million. For the three months ended March 31, 2024, Kintara reported a net loss of approximately $2.0 million, or $0.05 per share, compared to a net loss of approximately $3.3 million, or $1.94 per share, for the three months ended March 31, 2023.”
TuHURA Biosciences, Inc./NV entered into Agreement and Plan of Merger with Kintara Therapeutics, Inc., Kayak Mergeco, Inc. (effective 2024-04-02).
“On April 2, 2024, Kintara Therapeutics, Inc. (“ Kintara ”), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware (“ Merger Sub ”), and TuHURA Biosciences, Inc., a Delaware corporation (“ TuHURA ”), entered into an Agreement and Plan of Merger”
TuHURA Biosciences, Inc./NV reported fiscal 2024 second quarter ended December 31, 2023 results: net income $1.0 million, EPS $0.24 per share.
“For the three months ended December 31, 2023, Kintara reported a net loss of approximately $1.0 million, or $0.24 per share”
TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 13, 2023, Kintara Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pri”
TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).
“November 6, 2023, the Company submitted to the Staff a plan to regain compliance with the Stockholders’ Equity Requirement. On December 4, 2023, the Staff provided notice (the “Notice”) to the Company that it granted an extension of up to 180 days from September 20, 2023, or through March 18, 2024, to regain compliance with the Stockholders’ Equity Requirement, conditioned upon the Company’s achievement of certain milestones included in the plan of compliance previously submitted to the Staff. If the Company fails to evidence compliance upon filing its periodic report for the quarter ending Ma”
Dennis Brown was terminated as Chief Scientific Officer at TuHURA Biosciences, Inc./NV.
“on November 20, 2023, Dennis Brown was terminated from his position as the Company’s Chief Scientific Officer, effective immediately.”
TuHURA Biosciences, Inc./NV reported fiscal first quarter ended September 30, 2023 results: net income approximately $3.0 million, or $1.83 per share, EPS $1.83 per share (basic and diluted loss per share from net loss attributable to common stockholders).
“For the three months ended September 30, 2023, Kintara reported a net loss of approximately $3.0 million, or $1.83 per share, compared to a net loss of approximately $4.6 million, or $3.39 per share, for the three months ended September 30, 2022.”
TuHURA Biosciences, Inc./NV shareholders approved Approve adjournment of special meeting if needed at the 2023-10-09 meeting.
“The votes cast with respect to the proposal to approve the adjournment of the Special Meeting in the event that the number of shares of the Company’s common stock and Series C Preferred Stock present or represented by proxy at the Special Meeting and voting “FOR” the adoption of Proposal 1 were insufficient were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 647,100 36,634 1,841 0”
TuHURA Biosciences, Inc./NV shareholders approved Approve issuance of more than 20% of common stock under purchase agreement with Lincoln Park Capital Fund, LLC at the 2023-10-09 meeting.
“The votes cast with respect to the proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund, LLC were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 644,145 39,208 2,222 0”
TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“September 20, 2023, Kintara Therapeutics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, the Company reported stockholders’ equity of $73”
TuHURA Biosciences, Inc./NV entered into Sales Agreement with A.G.P./Alliance Global Partners valued at $2.85 million (effective 2023-09-19).
“On September 19, 2023, Kintara Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $2.85 million (“Shares”), subject to certain limitations on the amount of Common Stock that may be offered and sold by the Company set forth in the Sales Agreement (the “Offering”).”
TuHURA Biosciences, Inc./NV reported the fiscal year ended June 30, 2023 results: net income a net loss of approximately $14.6 million, or $9.27 per share, EPS $9.27 per share.
“For the year ended June 30, 2023, Kintara reported a net loss of approximately $14.6 million, or $9.27 per share, compared to a net loss of approximately $22.7 million, or $25.80 per share, for the year ended June 30, 2022.”
TuHURA Biosciences, Inc./NV: Amendment to Articles of Incorporation to increase authorized shares of common stock from 5,500,000 to 75,000,000 (effective 2023-06-30).
“As described under Proposal 2 of Item 5.07 of this Current Report, on June 30, 2023, the stockholders of Kintara Therapeutics, Inc. (the “Company”) voted at the Company’s reconvened 2023 Annual Meeting of Stockholders (the “Annual Meeting”), which was adjourned on May 8, 2023, May 25, 2023 and June 15, 2023, to approve an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), to increase the number of authorized shares of common stock, par value of $0.001 per share (“Common Stock”) from 5,500,000 to 75,000,000 shares.”
TuHURA Biosciences, Inc./NV shareholders approved Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending June 30, 2023 at the 2023-06-30 meeting.
“4. The votes cast with respect to the proposal to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending June 30, 2023 were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 1,193,957 32,888 11,781 0 The stockholders approved the proposal to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023.”
TuHURA Biosciences, Inc./NV shareholders approved Approval of an adjournment of the Annual Meeting in the event that the number of shares of Common Stock and Series C Preferred Stock present or represented by proxy at the Annual Meeting and voting “FOR” the adoption of the Charter Amendment Proposal were insufficient at the 2023-06-30 meeting.
“3. The votes cast with respect to the proposal to approve an adjournment of the Annual Meeting in the event that the number of shares of Common Stock and Series C Preferred Stock present or represented by proxy at the Annual Meeting and voting “FOR” the adoption of the Charter Amendment Proposal were insufficient were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 1,025,325 187,720 25,581 0 The stockholders approved the proposal to adjourn the Annual Meeting if needed.”
TuHURA Biosciences, Inc./NV shareholders approved Adoption of an amendment to the Articles of Incorporation to increase the number of shares of Common Stock available for issuance thereunder from 5,500,000 to 75,000,000 shares at the 2023-06-30 meeting.
“2. The votes cast with respect to the proposal to adopt an amendment to the Articles of Incorporation to increase the number of shares of Common Stock available for issuance thereunder from 5,500,000 to 75,000,000 shares were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 970,365 264,177 4,084 0 The stockholders approved the proposal to adopt the amendment to the Articles of Incorporation.”
TuHURA Biosciences, Inc./NV shareholders approved The proposal to elect the following nominees, Robert E. Hoffman, Robert J. Toth, Jr., Laura Johnson, and Tamara A. Favorito, as directors of the Company to hold office until the next annual meeting and until his or her successor has been duly elected and qualified, or, if sooner, until the director’ at the 2023-06-30 meeting.
“The voting results for each item of business voted upon at the Annual Meeting were as follows: 1. The proposal to elect the following nominees, Robert E. Hoffman, Robert J. Toth, Jr., Laura Johnson, and Tamara A. Favorito, as directors of the Company to hold office until the next annual meeting and until his or her successor has been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. FOR WITHHELD BROKER NON-VOTES Robert E. Hoffman 809,194 56,121 373,311 Robert J. Toth, Jr. 803,679 61,636 373,311 Laura Johnson 806,691 58,624 373,311 Tamara A. Favorito 806,805 58,510 373,311 The stockholders elected each nominee as a director of the Company.”
Robert E. Hoffman was appointed as interim Chief Financial Officer at TuHURA Biosciences, Inc./NV.
“On June 1, 2023, the Company’s Board of Directors (the “Board”) appointed Robert E. Hoffman, the current President, Chief Executive Officer, and Chairman of the Board of the Company, to succeed Mr. Praill as the Company’s interim Chief Financial Officer.”
Scott Praill resigned as Chief Financial Officer at TuHURA Biosciences, Inc./NV.
“On May 30, 2023, Scott Praill resigned from his position as Chief Financial Officer of Kintara Therapeutics, Inc. (the “Company”), effective May 31, 2023.”
TuHURA Biosciences, Inc./NV reported the nine months ended March 31, 2023 results: net income net loss of approximately $11.3 million, EPS $7.32 per share.
“For the nine months ended March 31, 2023, Kintara reported a net loss of approximately $11.3 million, or $7.32 per share, compared to a net loss of approximately $17.2 million, or $22.39 per share, for the nine months ended March 31, 2022.”
TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2023 results: net income net loss of approximately $3.3 million, EPS $1.94 per share.
“For the three months ended March 31, 2023, Kintara reported a net loss of approximately $3.3 million, or $1.94 per share, compared to a net loss of approximately $5.4 million, or $5.45 per share, for the three months ended March 31, 2022.”
TuHURA Biosciences, Inc./NV shareholders approved Adjournment of the Annual Meeting to allow for additional time for stockholders to vote on the Charter Amendment Proposal at the 2023-05-08 meeting.
“The votes cast with respect to the Adjournment Proposal were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 880,144 197,908 25,535 0”
TuHURA Biosciences, Inc./NV reported fiscal year 2023 second quarter ended December 31, 2022 results: net income net loss of approximately $3.5 million, or $2.10 per share, EPS $2.10 per share.
“For the three months ended December 31, 2022, Kintara reported a net loss of approximately $3.5 million, or $2.10 per share, compared to a net loss of approximately $5.9 million, or $6.07 per share, for the three months ended December 31, 2021.”
TuHURA Biosciences, Inc./NV: Effected a one-for-fifty (1:50) reverse stock split of common stock and corresponding reduction in authorized shares via Certificate of Change to Articles of Incorporation (effective 2022-11-11).
“On November 10, 2022, Kintara Therapeutics, Inc. (the “Company”) filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, with the Secretary of State of the State of Nevada (the “Certificate of Change”), which effected, at 5:00 p.m. Eastern Time on November 11, 2022, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of both the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”) and authorized shares of Common Stock.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.